Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

Abstract:

:We have compared the effects of the progestin R5020 and the antiprogestin RU486 on the growth of the MCF-7 and T47D breast cancer cell lines. Differences between the two compounds were demonstrated in several parameters. 1. Estradiol was required for the efficient inhibition of cell growth of both lines by R5020 but not by RU486. Therefore in the total absence of estrogen (phenol-red free medium), the effects of the two drugs on cell growth were dissociated, RU486 remaining inhibitory while R5020 was inactive. 2. The proteins secreted by cells were differently affected, since R5020 induced a 48K protein and decreased the production of the estrogen-regulated 52K protein, while RU486 had no effect on these two parameters. 3. The morphology of cells treated by R5020 was more altered in the presence of estradiol than in its absence, while that of cells treated by RU486 was not affected whether or not estradiol was present. 4. There was a greater reduction of estrogen receptor sites in MCF-7 cells produced by R5020 than by RU486. Even though the two drugs appear to act through the same progesterone receptor and to inhibit total protein secretion, it is likely that they exert their antiproliferative effects on cultured breast cancer cells by different mechanisms. R5020 antagonizes the stimulation produced by estradiol. RU486 by contrast exerts a more direct progesterone receptor mediated inhibitory effect requiring no synergism by estradiol and therefore does not act through a partial progestin activity.

authors

Gill PG,Vignon F,Bardon S,Derocq D,Rochefort H

doi

10.1007/BF01806133

subject

Has Abstract

pub_date

1987-10-01 00:00:00

pages

37-45

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

10

pub_type

杂志文章
  • The impact of rehabilitation support services on health-related quality of life for women with breast cancer.

    abstract::As the number of women surviving breast cancer increases, with implications for the health system, research into the physical and psychosocial sequelae of the cancer and its treatment is a priority. This research estimated self-reported health-related quality of life (HRQoL) associated with two rehabilitation interven...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-5151-5

    authors: Gordon LG,Battistutta D,Scuffham P,Tweeddale M,Newman B

    更新日期:2005-10-01 00:00:00

  • Generation of CD8+ cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A-pulsed dendritic cells.

    abstract::Mammaglobin-A is exclusively expressed by breast cancer cells. Thus, mammaglobin-A-specific T cell immune responses may be useful for the design of new breast cancer-specific immunotherapies. We show herein that CD8+ T cells generated against recombinant mammaglobin-A-pulsed dendritic cells display a marked cytotoxic ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023323509888

    authors: Manna PP,Jaramillo A,Majumder K,Campbell LG,Fleming TP,Dietz JR,Dipersio JF,Mohanakumar T

    更新日期:2003-05-01 00:00:00

  • Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed.

    abstract:PURPOSE:Evaluation of the safety and efficacy of a combination of docetaxel and doxorubicin in breast cancer patients. Evaluation and comparison of the pathological complete response (pCR) to this regimen according to various definitions in different clinical trials. Utilize the data to propose standardization of defin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9889-9

    authors: Mukai H,Watanabe T,Ando M,Shimizu C,Katsumata N

    更新日期:2009-01-01 00:00:00

  • A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.

    abstract::To date, three molecular markers (ER, PR, and CYP2D6) have been used in clinical setting to predict the benefit of the anti-estrogen tamoxifen therapy. Our aim was to validate new biomarker candidates predicting response to tamoxifen treatment in breast cancer by evaluating these in a meta-analysis of available transc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-013-2622-y

    authors: Mihály Z,Kormos M,Lánczky A,Dank M,Budczies J,Szász MA,Győrffy B

    更新日期:2013-07-01 00:00:00

  • Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers.

    abstract::Co-transfection studies indicate that HER2 (erbB-2) overexpression results in the phosphorylation and enhanced transcriptional activity of the androgen receptor (AR). This amplification of AR action is further enhanced by the expression of ARA70, a putative co-activator with a predilection for the AR. Because androgen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1017938608460

    authors: Kollara A,Kahn HJ,Marks A,Brown TJ

    更新日期:2001-06-01 00:00:00

  • Chromosome 11q13 markers and D-type cyclins in breast cancer.

    abstract::One in six primary human breast cancers has DNA amplification centered on the cyclin D1 gene (CCND1) on chromosome 11q13. This genetic abnormality is preferentially associated with estrogen-receptor positive tumors and may define a sub-class of patients with an adverse prognosis. Although CCND1 has the credentials of ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00682720

    authors: Peters G,Fantl V,Smith R,Brookes S,Dickson C

    更新日期:1995-01-01 00:00:00

  • Multiple growth factor independence in rat mammary carcinoma cells.

    abstract::In previous studies we demonstrated that rat mammary tumor (RMT) cells that are serially transplantable consist of cells that are independent of growth factors strictly required by normal rat mammary epithelial (RME) cells for growth in serum-free culture. The present studies were designed to determine the extent of t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01980969

    authors: Ethier SP,Moorthy R

    更新日期:1991-05-01 00:00:00

  • International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases.

    abstract::Recently, many centers have omitted routine axillary lymph node dissection (ALND) after metastatic sentinel node biopsy in breast cancer due to a growing body of literature. However, existing guidelines of adjuvant treatment planning are strongly based on axillary nodal stage. In this study, we aim to develop a novel ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-013-2468-3

    authors: Meretoja TJ,Audisio RA,Heikkilä PS,Bori R,Sejben I,Regitnig P,Luschin-Ebengreuth G,Zgajnar J,Perhavec A,Gazic B,Lázár G,Takács T,Kővári B,Saidan ZA,Nadeem RM,Castellano I,Sapino A,Bianchi S,Vezzosi V,Barranger E,L

    更新日期:2013-04-01 00:00:00

  • The value of embedding: integrated palliative care for patients with metastatic breast cancer.

    abstract:PURPOSE:The American Society of Clinical Oncology recommends concurrent palliative care (PC) for patients with metastatic cancer. Recent data show benefits of early PC (at least 90 days before death). However, little is known about PC among patients who die from metastatic breast cancer. METHODS:Patients with metastat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-017-4556-2

    authors: Rabow M,Small R,Jow A,Majure M,Chien A,Melisko M,Belkora J,Esserman LJ,Rugo H

    更新日期:2018-02-01 00:00:00

  • Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors.

    abstract::Clinical practice guidelines recommend yearly surveillance mammography for breast cancer survivors, yet many women do not receive this service. The objective of this study was to evaluate factors related to long-term surveillance mammography adherence among breast cancer survivors. We conducted a retrospective cohort ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2816-3

    authors: Wirtz HS,Boudreau DM,Gralow JR,Barlow WE,Gray S,Bowles EJ,Buist DS

    更新日期:2014-02-01 00:00:00

  • Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.

    abstract::Breast tumor infiltrating lymphocytes (TIL) are enriched in tumor-specific cytotoxic T lymphocytes (CTL), and may represent a superior source of CTL compare to peripheral blood lymphocytes (PBL), for adoptive T cell immunotherapy of breast cancer. However, the immunocompetence of TIL and the possibility to consistentl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/A:1024938215782

    authors: Kass R,Bellone S,Palmieri M,Canè S,Bignotti E,Henry-Tillman R,Hutchins L,Cannon MJ,Klimberg S,Santin AD

    更新日期:2003-08-01 00:00:00

  • Assessing the additional surgical risk of contralateral prophylactic mastectomy and immediate breast implant reconstruction.

    abstract:INTRODUCTION:There has been a sharp rise in the rate of contralateral prophylactic mastectomy over the last decade, despite the low incidence of new primary cancers predicted for the contralateral breast. This study compares the postoperative complication rates between the diseased breast treated with mastectomy and th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05460-0

    authors: Nealon KP,Sobti N,Gadd M,Specht M,Liao EC

    更新日期:2020-01-01 00:00:00

  • Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.

    abstract::Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-fa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1946-8

    authors: Zhao X,Mirza S,Alshareeda A,Zhang Y,Gurumurthy CB,Bele A,Kim JH,Mohibi S,Goswami M,Lele SM,West W,Qiu F,Ellis IO,Rakha EA,Green AR,Band H,Band V

    更新日期:2012-07-01 00:00:00

  • Telomerase immortalization of human mammary epithelial cells derived from a BRCA2 mutation carrier.

    abstract::A novel human mammary epithelial cell line, HME348, was established from benign breast tissue from a 44-year-old germ-line BRCA2 mutation carrier with a history of stage 1 breast cancer. Mutation analysis showed that the patient had a known 6872del4 BRCA2 heterozygous mutation. The human mammary epithelial cells passa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9189-9

    authors: Lewis CM,Herbert BS,Bu D,Halloway S,Beck A,Shadeo A,Zhang C,Ashfaq R,Shay JW,Euhus DM

    更新日期:2006-09-01 00:00:00

  • Breast cancer in women under 30 years of age.

    abstract::Conflicting opinions exist concerning clinical and pathological presentation, as well as evolution and prognosis, of breast cancer in young women. The roles of associated pregnancy and lactation on these parameters is also unclear. These two conditions are studied in the present work through the comparison of two brea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF02235745

    authors: Tabbane F,el May A,Hachiche M,Bahi J,Jaziri M,Cammoun M,Mourali N

    更新日期:1985-01-01 00:00:00

  • Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study.

    abstract::Mortality due to causes other than breast cancer is a potential competing risk which may alter the incidence probability of breast cancer and as such should be taken into account in predictive modelling. We used data from the Canadian National Breast Screening Study (CNBSS), which consist of two randomized controlled ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2113-6

    authors: Taghipour S,Banjevic D,Fernandes J,Miller AB,Montgomery N,Harvey BJ,Jardine AK

    更新日期:2012-07-01 00:00:00

  • Hormone receptors and obesity in Japanese women with breast cancer.

    abstract::An association between hormone receptors in primary breast cancer and obesity determined prior to mastectomy was investigated in 128 Japanese women. The following criteria for obesity were used: (1) weight greater than or equal to 60 kg (132 lbs), (2) weight kg/height cm-105 greater than or equal to 1.3, (3) weight lb...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805867

    authors: Kuno K,Fukami A,Hori M,Kasumi F

    更新日期:1981-01-01 00:00:00

  • Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography.

    abstract:PURPOSE:Patients with spontaneous nipple discharge (SND) who have neither clinically palpable masses nor evidence of disease on imaging with mammogram and/or ultrasound are traditionally investigated with galactogram and duct excision. As breast imaging improves, it has raised the question whether galactography and mic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05109-4

    authors: Lustig DB,Warburton R,Dingee CK,Kuusk U,Pao JS,McKevitt EC

    更新日期:2019-04-01 00:00:00

  • Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women.

    abstract::Tamoxifen citrate is a synthetic antiestrogen that provides survival benefit when given as adjuvant treatment in postmenopausal women with breast cancer. Venous thrombophlebitis may complicate tamoxifen treatment at a rate of approximately one per 800 treatment-years. To explore the possible procoagulant effects assoc...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00665973

    authors: Mamby CC,Love RR,Feyzi JM

    更新日期:1994-01-01 00:00:00

  • Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

    abstract::The association between promoter methylation status and survival was investigated in a large cohort of women with breast cancer, participants in the Long Island Breast Cancer Study Project. Archived tumor tissues (n = 839) were collected from women diagnosed with a first primary invasive or in situ breast cancer in 19...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1712-y

    authors: Cho YH,Shen J,Gammon MD,Zhang YJ,Wang Q,Gonzalez K,Xu X,Bradshaw PT,Teitelbaum SL,Garbowski G,Hibshoosh H,Neugut AI,Chen J,Santella RM

    更新日期:2012-01-01 00:00:00

  • Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.

    abstract::In epithelial-to-mesenchymal transition (EMT) epithelial cancer cells achieve mesenchymal features, essentially helping them to metastasize. There is some evidence that EMT could be increased in triple-negative (TNBC) or basal-like breast cancers, although more precise mechanisms considering e.g. EMT-regulating transc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2442-0

    authors: Karihtala P,Auvinen P,Kauppila S,Haapasaari KM,Jukkola-Vuorinen A,Soini Y

    更新日期:2013-02-01 00:00:00

  • Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.

    abstract::We determined the expression of two transcriptional variants of thyroid hormone receptor alpha (THRα1 and THRα2) in samples from a cohort of breast cancer patients and correlated expression levels with survival. 130 women who were diagnosed with invasive breast carcinoma between 2007 and 2008 were included. Representa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3235-9

    authors: Jerzak KJ,Cockburn J,Pond GR,Pritchard KI,Narod SA,Dhesy-Thind SK,Bane A

    更新日期:2015-01-01 00:00:00

  • Knowledge and perceptions of familial and genetic risks for breast cancer risk in adolescent girls.

    abstract::Evidence suggests early events might modify adult breast cancer risk and many adolescents learn of familial and genetic risks for breast cancer. Little is known about how adolescent girls understand and respond to breast cancer risk. Semi-structured interviews with 11-19 year-old girls at high-risk and population-risk...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2254-7

    authors: Bradbury AR,Patrick-Miller L,Egleston BL,Schwartz LA,Sands CB,Shorter R,Moore CW,Tuchman L,Rauch P,Malhotra S,Rowan B,Van Decker S,Schmidheiser H,Bealin L,Sicilia P,Daly MB

    更新日期:2012-12-01 00:00:00

  • Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

    abstract::Tamoxifen is metabolized into endoxifen, a potent antagonist of the estrogen receptor, in part through cytochrome p450 (CYP) 2D6. Genotypic variation in CYP2D6 affects endoxifen levels, and some have argued that patients who do not efficiently metabolize tamoxifen might wish to consider alternative hormonal treatments...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-013-2700-1

    authors: Ruddy KJ,Desantis SD,Gelman RS,Wu AH,Punglia RS,Mayer EL,Tolaney SM,Winer EP,Partridge AH,Burstein HJ

    更新日期:2013-10-01 00:00:00

  • The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin.

    abstract::A detailed analysis of the immune system response has been performed during the development and progression of dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. For this aim, a number of immune parameters (thymocyte and splenocyte proliferative response to T-dependent mitogens, antibody production, lymphocy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665692

    authors: Gallo F,Morale MC,Sambataro D,Farinella Z,Scapagnini U,Marchetti B

    更新日期:1993-09-01 00:00:00

  • Differentially expressed genes associated with the metastatic phenotype in breast cancer.

    abstract::We have previously shown that human breast carcinoma cells demonstrating an interconverted phenotype, where keratin (epithelial marker) and vimentin (mesenchymal marker) intermediate filaments are both expressed, have an increased ability to invade a basement membrane matrix in vitro. This increase in invasive potenti...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006188129423

    authors: Kirschmann DA,Seftor EA,Nieva DR,Mariano EA,Hendrix MJ

    更新日期:1999-05-01 00:00:00

  • Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.

    abstract::Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3554-5

    authors: Buas MF,Rho JH,Chai X,Zhang Y,Lampe PD,Li CI

    更新日期:2015-09-01 00:00:00

  • A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.

    abstract::Numerous allelic variants identified in the familial breast cancer and DNA repair genes BRCA1 and BRCA2 are of unknown impact on protein function or clinical relevance, referred to as unclassified variants (UCV). Lymphocytes from pathogenic BRCA1/2 mutation carriers exhibit an increased level of chromosomal damage aft...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2119-0

    authors: Becker AA,Graeser MK,Landwehr C,Hilger T,Baus W,Wappenschmidt B,Meindl A,Weber RG,Schmutzler RK

    更新日期:2012-08-01 00:00:00

  • Association between thyroid gland diseases and breast cancer: a case-control study.

    abstract:BACKGROUND:At the present time, there is no consensus on the association between benign thyroid diseases and breast cancer (BC). Therefore, the aim of this study is to help shed some light on the association between hyperthyroidism, hypothyroidism, and thyroiditis and breast cancer risk. METHODS:Use of the Disease Ana...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05675-6

    authors: Bach L,Kostev K,Schiffmann L,Kalder M

    更新日期:2020-07-01 00:00:00

  • Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.

    abstract:BACKGROUND:Anastrozole, a new aromatase inhibitor, has been used to treat postmenopausal metastatic breast cancer, and several clinical trials of adjuvant treatment using this agent are ongoing. However, the effects of anastrozole on lipid metabolism are unknown. The aim of this study was to evaluate the effect of anas...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1020571617274

    authors: Hozumi Y,Hakamata Y,Sasanuma H,Ogura S,Nagai H

    更新日期:2002-11-01 00:00:00